ArticleJournal of medical biochemistry2025
Causal effects of inflammatory cytokines on hemangioma mediated by blood metabolites: A two-step Mendelian randomization study.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemangioma is the most prevalent infantile vascular tumor. The state of inflammation and metabolism may contribute to the occurrence and development of hemangioma, but their causal relationships have not been clearly elucidated. In this study, via Mendelian randomization (MR) analysis, we aimed to investigate the causal effect of inflammatory cytokines and blood metabolites on hemangioma, and to explore the potential mediating role of metabolites. Methods: Applying large-scale genome-wide association studies (GWAS) dataset, we applied two-sample Mr to infer causal relationships among 91 inflammatory cytokines, 1091 blood metabolites and 309 metabolite ratios and hemangioma. In addition, a two-step Mr was used to assess the potential mediating role of metabolites. Functional enrichment was also performed to explore the biological pathways involved. Results: 9 cytokines exhibited significant causal effects on hemangioma. Cytokines such as C-C motif chemokine 20 (CCL20), Interferon-y(IFN-y), Eotaxin and TNF-related activation-induced cytokine (TRANCE) were associated with an increased risk, while Interleukin-12 subunit beta(IL12B), C-X-C motif chemokine 11(CXCL11), Transforming growth factor-alpha (TGF-a), Oncostatin-M(OSM) and Interleukin-17A (IL17A) were inversely associated. Additionally, 52 blood metabolites and metabolite-ratios were discovered to have causal effects on hemangioma. 18 metabolites and metabolite-ratios were associated with an elevated risk of hemangioma, whereas 34 metabolites and metabolite-ratios appeared to be protective factors. Mediation analysis further identified specific metabolites, such as Gamma-glutamylvaline, as mediators in cytokine-hemangioma pathways, suggesting that they might modulate cytokine-driven tumorigenesis. Conclusions: As the first Mr study focused on hemangioma, we identified key cytokines and metabolites which might exert a causal effect on hemangioma, with several metabolites functioning as intermediators in cytokine-induced tumorigenesis process. The complex interaction between inflammation and metabolism in hemangioma was revealed, laying a foundation for future studies to explore potential targeted treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.